Collectively, the data support a reduction in host mediators (e.g., TLR-ATP, IL-1β, MMP-1, and MMP-9) with regimen treatment that are implicated in inflammation and periodontal disease destruction. This evidence concerns the gene IL1B and periodontal disorder.